Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, Anker SD, Atherton J, Böhm M, Butler J, et al. Universal definition, and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society, and Writing Committee of the Universal Definition of Heart Failure. Eur J Heart Fail. 2021;23(3):352–80. https://doi.org/10.1002/ejhf.2115.

Article  PubMed  Google Scholar 

Fonarow GC, Stough WG, Abraham WT, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure. J Am Coll Cardiol. 2007;50:768–77.

Article  PubMed  Google Scholar 

Borlaug BA, Sharma K, Shah SJ, Ho JE. Heart failure with preserved ejection fraction: JACC scientific statement. J Am Coll Cardiol. 2023;81:1810–34.

Article  PubMed  Google Scholar 

Pfeffer MA, Shah AM, Borlaug BA. Heart failure with preserved ejection fraction in perspective. Circ Res. 2019;24:124.

Google Scholar 

Bozkurt B, Ahmad T, Alexander KM, Baker WL, Bosak K, Breathett K, Fonarow GC, et al. Heart failure epidemiology and outcomes statistics: a report of the Heart Failure Society of America. J Card Fail. 2023;29(10):1412–51. https://doi.org/10.1016/j.cardfail.2023.07.006.

Article  PubMed  PubMed Central  Google Scholar 

Samson R, Jaiswal A, Ennezat PV, Cassidy M, Jemtel THL. Clinical phenotypes in heart failure with preserved ejection fraction. J Am Heart Assoc. 2016;25:5.

Google Scholar 

Heidenreich PA, Bozkurt B, Aguilar D, et al. AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;2022:145.

Google Scholar 

Kittleson MM, Panjrath GS, Amancherla K, et al. 2023 ACC Expert Consensus Decision Pathway on management of heart failure with preserved ejection fraction. J Am Coll Cardiol. 2023;9:81.

Google Scholar 

Goyal P, Kwak MJ, Al Malouf C, et al. Geriatric cardiology: coming of age. JACC Adv. 2022;1: 100070.

Article  PubMed  PubMed Central  Google Scholar 

Cherubini A, Oristrell J, Pla X, Ruggiero C, Ferretti R, Diestre G, et al. The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. Arch Intern Med. 2011;171:550–6.

Article  PubMed  Google Scholar 

Mullens W, Damman K, Harjola VP, et al. The use of diuretics in heart failure with congestion: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21:137–55.

Article  PubMed  Google Scholar 

Brater DC. Diuretic therapy. N Engl J Med. 1998;6:339.

Google Scholar 

Cuthbert JJ, Clark AL. Diuretic treatment in patients with heart failure: current evidence and future directions—part I: loop diuretics. Curr Heart Fail Rep. 2024;21:101–14.

Article  PubMed  PubMed Central  Google Scholar 

Kourouklis C, Christensen O, Augoustakis D. Bumetanide in congestive heart failure. Curr Med Res Opin. 1976;4:422–31.

Article  CAS  PubMed  Google Scholar 

Sherman LG, Liang C-S, Baumgardner S, Charuzi Y, Chardo F, Kim CS. Piretanide, a potent diuretic with potassium-sparing properties, for the treatment of congestive heart failure. Clin Pharmacol Ther. 1986;40:587–94.

Article  CAS  PubMed  Google Scholar 

Haerer W, Bauer U, Sultan N, et al. Acute and chronic effects of a diuretic monotherapy with piretanide in congestive heart failure—a placebo-controlled trial. Cardiovasc Drugs Ther. 1990;4:515–21.

Article  CAS  PubMed  Google Scholar 

Leung CC. Current role of the CardioMEMS device for management of patients with heart failure. Curr Cardiol Rep. 2019;21:98.

Article  PubMed  Google Scholar 

Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomized controlled trial. Lancet. 2011;377(9766):658–66.

Article  PubMed  Google Scholar 

Ellison DH. Clinical pharmacology in diuretic use. Clin J Am Soc Nephrol. 2019;14:1248–57.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Felker GM, Ellison DH, Mullens W, Cox ZL, Testani JM. Diuretic therapy for patients with heart failure: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(10):1178–95. https://doi.org/10.1016/j.jacc.2019.12.059.

Article  CAS  PubMed  Google Scholar 

Mentz RJ, Anstrom KJ, Eisenstein EL, et al. Effect of Torsemide vs furosemide after discharge on all-cause mortality in patients hospitalized with heart failure. JAMA. 2023;329:214.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Miller WL. Fluid volume homeostasis in heart failure: a tale of 2 circulations. J Am Heart Assoc. 2022;11(18):e026668

Levin SN, Hajduk AM, McManus DD, et al. Cognitive status in patients hospitalized with acute decompensated heart failure. Am Heart J. 2014;168:917–23.

Article  PubMed  PubMed Central  Google Scholar 

Ellison DH, Felker GM. Diuretic treatment in heart failure. N Engl J Med. 2017;377(20):1964–75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Denfeld QE, Turrise S, Maclaughlin EJ, et al. Preventing and managing falls in adults with cardiovascular disease: a scientific statement from the American Heart Association. Circ Cardiovasc Qual Outcomes. 2022;15(6):e000108.

Montero D, Flammer AJ. Exercise intolerance in heart failure with preserved ejection fraction: time to scrutinize diuretic therapy? Eur J Heart Fail. 2017;19:971–3.

Article  PubMed  Google Scholar 

Casu G, Merella P. Diuretic therapy in heart failure—current approaches. Eur Cardiol Rev. 2015;10:42.

Article  Google Scholar 

Ferreira JP, Butler J, Rossignol P, et al. Abnormalities of potassium in heart failure. J Am Coll Cardiol. 2020;75:2836–50.

Article  CAS  PubMed  Google Scholar 

Edelmann F, Wachter R, Schmidt AG, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction. JAMA. 2013;309:781.

Article  CAS  PubMed  Google Scholar 

Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383–92.

Article  CAS  PubMed  Google Scholar 

Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation. 2015;131:34–42.

Article  CAS  PubMed  Google Scholar 

Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction, SPIRRIT-HFPEF. Uppsala University.

Vardeny O, Claggett B, Vaduganathan M, et al. Influence of age on efficacy and safety of spironolactone in heart failure. JACC Heart Fail. 2019;7:1022–8.

Article  PubMed  Google Scholar 

Neuen BL, Oshima M, Agarwal R, et al. Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials. Circulation. 2022;145:1460–70.

Article  CAS  PubMed  Google Scholar 

Wilcox CS. Antihypertensive and renal mechanisms of SGLT2 (sodium-glucose linked transporter 2) inhibitors. Hypertension. 2020;75:894–901.

Article  CAS  PubMed  Google Scholar 

Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61:10.

Article  Google Scholar 

Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med. 2017;104:298–310.

Article  CAS  PubMed  Google Scholar 

Kang S, Verma S, Teng G, et al. Direct effects of empagliflozin on extracellula